Revolution Medicines Inc.
Revolution Medicines Announces Third Quarter 2024 Financial Results and Corporate Updates
Summary
Revolution Medicines, Inc. announced its financial results for the quarter ended September 30, 2024, reporting a cash position of $1.55 billion. The company incurred a net loss of $156.3 million for the quarter. The company is progressing with clinical trials for its RAS(ON) inhibitors, including RMC-6236 in Phase 3 and RMC-9805 in early-stage trials. Financial results indicate higher R&D expenses due to clinical trial activities. Revolution Medicines expects its current cash reserves to fund operations into 2027.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement